Ghana stopped mass drug administration (MDA) for lymphatic filariasis in 92% of endemic health districts (HDs); 106 out of 114 HDs as of FY22 (October 2021 – September 2022).
Ghana was validated by the World Health Organization as having eliminated trachoma as a public health problem in 2018—the first nation in sub-Saharan Africa to achieve this.
61 health districts have completed a Stop MDA survey for onchocerciasis in FY22 (October 2021 – September 2022) to determine whether to stop mass drug administration in 2 endemic transmission zones.
Ghana was one of four countries in West Africa selected by the Task Force for Global Health to conduct a SCH Oversampling survey in three districts in 2022. Ghana also conducted its second schistosomiasis/soil-transmitted helminthiasis (SCH/STH) impact survey (the first re-assessment was in 2015) in nine districts in September 2022. The data from both surveys will be discussed at a data review meeting in January 2023 to re-assess the country’s treatment strategy going forward. In addition, another 20 districts have been approved to conduct more impact assessments in 2023.
Standard Disease-Specific Indicators as of FY21
FY21 is October 2020 through September 2021
of ever-endemic districts have stopped mass drug administration (MDA) as of FY21
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))
of ever-endemic districts in post-surveillance phase as of FY21
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY21 among those who were ever at risk
Ghana, which received support from USAID through the End in Africa program, was validated by the WHO as having eliminated trachoma as a public health problem in 2018.
of ever endemic districts have been treated at least once as of FY21
(in cases where a country has more treated districts reported than, ever endemic, the adjusted percent is 100%)